Secretin - Sanochemia

Drug Profile

Secretin - Sanochemia

Alternative Names: Secrelux

Latest Information Update: 14 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanochemia Pharmazeutika
  • Class Antipsychotics; Gastrointestinal hormones; Neuropeptides; Peptide diagnostics; Peptide hormones
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pancreatic disorders; Zollinger-Ellison syndrome
  • Clinical Phase Unknown Pancreatitis

Most Recent Events

  • 14 Oct 2015 Clinical trials in Pancreatitis in Europe (IV) (Sanochemia pipeline, October 2015)
  • 14 May 2013 Sanochemia's porcine synthetic secretin licensed to LINK Healthcare in Australia, New Zealand, Japan, South Africa and Asia (excluding Philippines and South Korea)
  • 30 Sep 2005 No development reported - Clinical-Phase-Unknown for Pancreatitis in Europe (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top